Serdemetan

CAS No. 881202-45-5

Serdemetan( JNJ 26854165 | JNJ26854165 | JNJ-26854165 )

Catalog No. M16390 CAS No. 881202-45-5

Serdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 35 In Stock
5MG 58 In Stock
10MG 87 In Stock
25MG 178 In Stock
50MG 335 In Stock
100MG 500 In Stock
500MG 1098 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Serdemetan
  • Note
    Research use only, not for human use.
  • Brief Description
    Serdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2.
  • Description
    Serdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2, dose-dependently inhibits proliferation in both wild-type and mutant p53 cell lines with IC50 of 0.25-3 uM; induces p53-mediated apoptosis in acute leukemia cells with wild-type p53, accelerates the proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53, induces S-phase delay and upregulates E2F1 expression in p53 mutant cells; demonstrates radiosensitizing activity in vitro and in tumor xenografts.Lung Cancer Phase 1 Discontinued.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    JNJ 26854165 | JNJ26854165 | JNJ-26854165
  • Pathway
    Apoptosis
  • Target
    MDM2-p53
  • Recptor
    HDM2|Mdm2|p53
  • Research Area
    Cancer
  • Indication
    Lung Cancer

Chemical Information

  • CAS Number
    881202-45-5
  • Formula Weight
    328.4103
  • Molecular Formula
    C21H20N4
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    C1(NCCC2=CNC3=C2C=CC=C3)=CC=C(NC4=CC=NC=C4)C=C1
  • Chemical Name
    1,4-Benzenediamine, N1-[2-(1H-indol-3-yl)ethyl]-N4-4-pyridinyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kojima K, et al. Mol Cancer Ther. 2010 Sep;9(9):2545-57. 2. Tabernero J, et al. Clin Cancer Res. 2011 Oct 1;17(19):6313-21. 3. Chargari C, et al. Cancer Lett. 2011 Dec 22;312(2):209-18. 4. Jones RJ, et al. J Pharmacol Exp Ther. 2013 Sep;346(3):381-92.
molnova catalog
related products
  • NSC-66811

    A potent, MDM2-p53 interaction inhibitor with Ki of 120 nM, activates p53 in cancer cells.

  • Relugolix

    Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity.

  • Nutlin-3

    Nutlin-3 is MDM2 antagonist. Nutlin-3 inhibits the MDM2-p53 interaction (IC50 = 0.09 μM) and activates p53.